keyword
MENU ▼
Read by QxMD icon Read
search

Psoriasis definition

keyword
https://www.readbyqxmd.com/read/28790550/paradoxical-side-effect-related-with-anti-tumor-necrosis-factor-alpha-treatment
#1
Ayhan Aşkın, Ece Güvendi, Aliye Tosun, Ümit Seçil Demirdal
INTRODUCTION: Anti-tumor necrosis factor (anti-TNF) treatments are effective in controlling disease activity in many immune-mediated diseases such as psoriasis and ankylosing spondylitis (AS). Although side effects such as infection and skin reactions are predictable in anti-TNF treatment; susceptibility to psoriasis is considered as a paradoxical side effect. CASE REPORT: We report a case of forty-year-old male patient with 7 years of AS was taking anti-TNF therapy...
April 2017: Medical Archives
https://www.readbyqxmd.com/read/28735350/inflammatory-joint-disorders-and-neutrophilic-dermatoses-a-comprehensive-review
#2
REVIEW
Massimo Cugno, Roberta Gualtierotti, Pier Luigi Meroni, Angelo Valerio Marzano
Rheumatoid arthritis and spondyloarthritis are inflammatory joint disorders with an autoimmune pathogenesis and systemic involvement. The skin is one of the most frequently affected extraarticular sites with a number of manifestations or distinct diseases, including common conditions, such as rheumatoid nodules and psoriasis, and rare diseases like neutrophilic dermatoses. The latter are clinically characterised by polymorphic lesions, including pustules, bullae, abscesses, papules, nodules, plaques and ulcers, and histologically by neutrophil-rich inflammatory infiltrates...
July 22, 2017: Clinical Reviews in Allergy & Immunology
https://www.readbyqxmd.com/read/28686780/a-survey-assessment-of-us-dermatologists-perception-of-biosimilars
#3
Alexandra Barsell, Monica Rengifo-Pardo, Alison Ehrlich
<p>BACKGROUND: Biologics have transformed the treatment of psoriasis and psoriatic arthritis, but at a significant cost to payers and patients. The introduction of biosimilars into the US market could reduce costs while increasing access to biologic medications.</p> <p>OBJECTIVE: We sought to identify gaps in biosimilar knowledge and perception among US dermatologists.</p> <p>METHODS: An online survey was sent to dermatologists from January to April 2015.</p> <p>RESULTS: Ninety-seven US dermatologists responded, of which 84% state they prescribe biologics in their practice...
June 1, 2017: Journal of Drugs in Dermatology: JDD
https://www.readbyqxmd.com/read/28674914/the-relevance-of-serum-vitamin-d-in-psoriasis-a-review
#4
REVIEW
R Hambly, B Kirby
Observational research has identified low serum levels of 25-hydroxyvitamin D (25[OH]D) in many non-skeletal diseases. Whether this is causal or due to underlying illness is unknown. Low serum 25[OH]D levels are also reported in the general population. Observational and experimental studies identify that vitamin D supplementation may be beneficial in reducing all-cause mortality in elderly women, as well as cancer mortality. Our aim was to review the literature to identify the relevance of serum 25[OH]D levels in psoriasis...
July 3, 2017: Archives of Dermatological Research
https://www.readbyqxmd.com/read/28646580/biosimilars-for-psoriasis-worldwide-overview-of-regulatory-guidelines-uptake-and-implications-for-dermatology-clinical-practice
#5
REVIEW
A D Cohen, J J Wu, L Puig, S Chimenti, R Vender, M Rajagopalan, R Romiti, C de la Cruz, L Skov, C Zachariae, H S Young, P Foley, J M van der Walt, L Naldi, A Blauvelt
The introduction of biologic drugs for the treatment of patients with psoriasis has revolutionized treatment paradigms and enabled numerous patients to achieve disease control with an acceptable safety profile. However, the high cost of biologics limits access to these medications for the majority of patients worldwide. In recent years, the introduction of biosimilars for inflammatory diseases has become a fast evolving field. The future use of biosimilars offers the potential for decreased cost and increased access to biologic drugs for patients with psoriasis...
June 24, 2017: British Journal of Dermatology
https://www.readbyqxmd.com/read/28627278/methotrexate-for-the-treatment-of-pediatric-alopecia-areata
#6
Erin T Landis, Rita O Pichardo-Geisinger
PURPOSE: Alopecia areata is a form of nonscarring hair loss that occurs in pediatric and adult patients, with presentation varying from round or ovoid patches of alopecia to alopecia totalis or universalis. While frustrating for patients, it can also be frustrating for clinicians to treat, as there is no definitive treatment. Dermatologists are very familiar with the use of methotrexate for psoriasis and other inflammatory skin diseases, and this medication is generally well tolerated in children...
June 30, 2017: Journal of Dermatological Treatment
https://www.readbyqxmd.com/read/28602842/immune-responses-and-parasitological-observations-induced-during-probiotic-treatment-with-medicinal-trichuris-suis-ova-in-a-healthy-volunteer
#7
Andrew R Williams, Anders Dige, Tue Kruse Rasmussen, Christian L Hvas, Jens F Dahlerup, Lars Iversen, C Rune Stensvold, Jørgen Agnholt, Peter Nejsum
Ingestion of eggs (ova) of the porcine nematode parasite Trichuris suis (TSO) may reduce the severity of autoimmune disorders, however the development of TSO treatment as a useful therapy for autoimmune diseases is hampered by a lack of knowledge on the development of the parasite and the nature of the local immune responses in humans. Here, we used colonoscopy to investigate the development of T. suis and related mucosal and systemic immune responses during TSO treatment in an intestinally healthy male volunteer...
August 2017: Immunology Letters
https://www.readbyqxmd.com/read/28581873/budget-impact-model-in-moderate-to-severe-psoriasis-vulgaris-assessing-effects-of-calcipotriene-and-betamethasone-dipropionate-foam-on-per-patient-standard-of-care-costs
#8
Carl V Asche, Minchul Kim, Steven R Feldman, Panagiotis Zografos, Minyi Lu
AIMS: To develop a budget impact model (BIM) for estimating the financial impact of formulary adoption and uptake of calcipotriene and betamethasone dipropionate (C/BD) foam (0.005%/0.064%) on the costs of biologics for treating moderate-to-severe psoriasis vulgaris in a hypothetical US healthcare plan with 1 million members. METHODS: This BIM incorporated epidemiologic data, market uptake assumptions, and drug utilization costs, simulating the treatment mix for patients who are candidates for biologics before (Scenario #1) and after (Scenario #2) the introduction of C/BD foam...
September 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28569222/is-the-current-asas-expert-definition-of-a-positive-family-history-useful-in-identifying-axial-spondyloarthritis-results-from-the-space-and-desir-cohorts
#9
Zineb Ez-Zaitouni, Andrea Hilkens, Laure Gossec, Inger Jorid Berg, Robert Landewé, Roberta Ramonda, Maxime Dougados, Désirée van der Heijde, Floris van Gaalen
BACKGROUND: The Assessment of SpondyloArthritis international Society (ASAS) definition of a positive family history (PFH) of spondyloarthritis (SpA) includes the following diseases in first- or second-degree relatives: ankylosing spondylitis (AS), acute anterior uveitis (AAU), reactive arthritis (ReA), inflammatory bowel disease (IBD), and psoriasis. However, it is not known if a PFH for each of these diseases contributes to making a diagnosis of axSpA, sacroiliitis on imaging, or fulfilling the ASAS criteria in patients presenting with chronic back pain (CBP)...
May 31, 2017: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/28557008/influence-of-tnf-alpha-inhibitors-and-fumaric-acid-esters-on-male-fertility-in-psoriasis-patients
#10
F Heppt, A Colsman, A Maronna, U Uslu, M V Heppt, F Kiesewetter, M Sticherling
OBJECTIVE: Is there any influence of a therapy with TNF alpha inhibitors or fumaric acid esters and of disease activity status on male fertility and sperm quality in psoriasis patients?. METHODS: In this monocentric, open-label, prospective study, semen samples were collected from patients receiving either TNF alpha inhibitors or fumaric acid esters for moderate to severe plaque psoriasis. Semen was analysed at baseline before onset of the systemic therapy and monitored every three months under therapy...
May 30, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28530055/-pulmonary-fibrosis-induced-by-anti%C3%B6-tnf-%C3%AE-lpha-treatment
#11
Sharon Baum, Orit Schachter, Aviv Barzilai
INTRODUCTION: TNFα-targeted therapies have emerged as a new class of drugs in the treatment of various inflammatory diseases, including psoriasis. With the increasing use and longer follow-up periods of TNFα targeted therapies, a spectrum of immunological adverse events have been described, ranging from asymptomatic immunological alterations to life-threatening systemic diseases such as pulmonary fibrosis. We present a case of a 66 year old man diagnosed with psoriasis who developed pulmonary fibrosis three years after initiation of Etanercept (Enbrel) for his skin disease...
October 2016: Harefuah
https://www.readbyqxmd.com/read/28427708/increased-incidence-and-prevalence-of-psoriasis-in-multiple-sclerosis
#12
Ruth Ann Marrie, Scott B Patten, Helen Tremlett, Christina Wolfson, Stella Leung, John D Fisk
BACKGROUND: Psoriasis and multiple sclerosis (MS) share some risk factors, and fumarates are effective disease-modifying therapies for both psoriasis and MS, suggesting a common pathogenesis. However, findings regarding the occurrence of psoriasis in the MS population are inconsistent. OBJECTIVES: We aimed to estimate the incidence and prevalence of psoriasis in the MS population versus a matched cohort from the general population. METHODS: We used population-based administrative data from the Canadian province of Manitoba to identify 4911 persons with MS and 23,274 age-, sex- and geographically-matched controls aged 20 years and older...
April 2017: Multiple Sclerosis and related Disorders
https://www.readbyqxmd.com/read/28249066/global-skin-disease-morbidity-and-mortality-an-update-from-the-global-burden-of-disease-study-2013
#13
Chante Karimkhani, Robert P Dellavalle, Luc E Coffeng, Carsten Flohr, Roderick J Hay, Sinéad M Langan, Elaine O Nsoesie, Alize J Ferrari, Holly E Erskine, Jonathan I Silverberg, Theo Vos, Mohsen Naghavi
Importance: Disability secondary to skin conditions is substantial worldwide. The Global Burden of Disease Study 2013 includes estimates of global morbidity and mortality due to skin diseases. Objective: To measure the burden of skin diseases worldwide. Data Sources: For nonfatal estimates, data were found by literature search using PubMed and Google Scholar in English and Spanish for years 1980 through 2013 and by accessing administrative data on hospital inpatient and outpatient episodes...
May 1, 2017: JAMA Dermatology
https://www.readbyqxmd.com/read/28223746/could-psoriatic-arthritis-be-easily-diagnosed-from-current-suspicious-physical-findings-in-the-dermatology-clinic
#14
Jee Woong Choi, Bo Ri Kim, Eunmi Seo, Sang Woong Youn
BACKGROUND: The prevalence and clinical characteristics of psoriatic arthritis (PsA) in patients with psoriasis are not well described in Asian populations, including Koreans. OBJECTIVE: The purpose of this study was to investigate the prevalence of PsA by using the classification of psoriatic arthritis (CASPAR) criteria on the basis of physical examination only, as well as its correlation with psoriasis severity and other medical conditions including nail psoriasis...
February 2017: Annals of Dermatology
https://www.readbyqxmd.com/read/28168661/psoriasis-in-systemic-lupus-erythematosus-a-single-center-experience
#15
Konstantinos Tselios, Kristy Su-Ying Yap, Rattapol Pakchotanon, Ari Polachek, Jiandong Su, Murray B Urowitz, Dafna D Gladman
The coexistence of psoriasis with systemic lupus erythematosus (SLE) has been reported in limited case series, raising hypotheses about shared pathogenetic mechanisms. Nevertheless, important differences regarding treatment do exist. The aim of the present study was to determine the prevalence and characteristics of psoriasis in a defined cohort of lupus patients. Patients with psoriasis were retrieved from the University of Toronto Lupus Clinic from its inception in 1970 up to 2015. Charts were hand-searched to collect information concerning demographic, clinical, and therapeutic variables...
April 2017: Clinical Rheumatology
https://www.readbyqxmd.com/read/28092253/-mexican-treatment-goals-for-plaque-psoriasis
#16
Lorena Estrada-Aguilar, Mario Amaya-Guerra, Minerva Gómez-Flores, Esther Guevara-Sanginés, Fermín Jurado-Santacruz, Adriana Lopeztello-Santillán, César Maldonado-García, Mónica Rivera-Gómez, Norma Rodríguez-Martínez, Luis Vega-González
Psoriasis is a chronic inflammatory disease with a worldwide prevalence between 6 and 39% in moderate to severe forms. In European countries like Germany and England was identified that only one third of patients with moderate to severe forms will receive systemic management, this fact motivated to integrate into Europe an international consensus on treatment goals with the aim of providing support to the dermatologist by algorithms that serve as a therapeutic guide that allows you to gain control short and long term effects of this disease...
January 2017: Revista Médica del Instituto Mexicano del Seguro Social
https://www.readbyqxmd.com/read/28064543/itolizumab-a-novel-anti-cd6-monoclonal-antibody-a-safe-and-efficacious-biologic-agent-for-management-of-psoriasis
#17
REVIEW
Sunil Dogra, Shraddha Uprety, Swaroop Hassan Suresh
Psoriasis, a chronic immune-mediated skin disorder is associated with significant physical, psychological, and quality of life impairments. Along with well-documented genetic and environmental factors, immunological factors also contribute to the pathogenesis of psoriasis. Among the immunological factors, CD6 - dependent T-cell proliferation to form Th1 and Th17 cells play a major role in the pathogenesis of psoriasis. Itolizumab is the first humanized IgG1 monoclonal antibody, which selectively targets CD6...
March 2017: Expert Opinion on Biological Therapy
https://www.readbyqxmd.com/read/28058749/is-psoriasis-an-autoimmune-disease-interpretations-from-an-immunofluorescence-based-study
#18
Shashi Anand, Parikshaa Gupta, Ranjeet Bhardwaj, Tarun Narang, Sunil Dogra, Ranjana W Minz, Biman Saikia, Seema Chhabra
INTRODUCTION: Psoriasis is a multisystem, immune-mediated inflammatory disease. Some authors have proposed an autoimmune basis for psoriasis; however, till date, it has not been definitely established. This study was conducted to explore the autoimmune nature of psoriasis. MATERIALS AND METHODS: This was a prospective study in which 43 psoriasis patients were assessed for detailed clinical, histopathological and immunopathological features to explore the diagnostic utility of subtypes, intensity and number of immunoreactants in lesional and non-lesional skin in these patients...
April 2017: Journal of Cutaneous Pathology
https://www.readbyqxmd.com/read/28027825/inflammatory-bowel-disease-among-patients-with-psoriasis-treated-with-ixekizumab-a-presentation-of-adjudicated-data-from-an-integrated-database-of-7-randomized-controlled-and-uncontrolled-trials
#19
Kristian Reich, Craig Leonardi, Richard G Langley, Richard B Warren, Hervé Bachelez, Ricardo Romiti, Mamitaro Ohtsuki, Wen Xu, Nayan Acharya, Kathleen Solotkin, Jean-Frederic Colombel, Dana S Hardin
BACKGROUND: Inflammatory bowel disease (IBD) occurs more frequently in patients with psoriasis. The 2 diseases have significant genetic overlap, but the pathogenesis underlying their co-occurrence is unknown. OBJECTIVE: We sought to report adjudicated IBD cases (Crohn's disease [CD] and ulcerative colitis [UC]) in patients exposed to ixekizumab, a high-affinity monoclonal antibody that selectively targets interleukin-17A. METHODS: Adverse events (AEs) integrated from 7 randomized controlled and uncontrolled trials were analyzed for the controlled induction period, controlled maintenance period, and all ixekizumab-treated patients...
March 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/27931515/autologous-adipose-derived-mesenchymal-stromal-cells-for-the-treatment-of-psoriasis-vulgaris-and-psoriatic-arthritis-a-case-report
#20
Miguel M De Jesus, Jayson S Santiago, Camille V Trinidad, Melvin E See, Kimberly R Semon, Manuel O Fernandez, Francisco S Chung
Psoriasis is a dermatologic disease of immune origins with no definitive cure. We report the Makati Medical Center experience of utilizing autologous mesenchymal stromal cells (MSCs) for one patient with psoriasis vulgaris (PV) and another with psoriatic arthritis (PA). Patients were educated and gave informed consent, according to the principles of the Declaration of Helsinki. The protocol was approved by the Cellular Transplantation Ethics Committee of the Makati Medical Center. Autologous MSCs were cultured from lipoaspirate and expanded in a clean room class 100 facility (Cellular Therapeutics Center, Makati Medical Center)...
November 2016: Cell Transplantation
keyword
keyword
110315
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"